{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:50:44Z","timestamp":1794304244977,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T00:00:00Z","timestamp":1525824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4477-4","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T14:02:45Z","timestamp":1525874565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Paul M.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilmurodjon","family":"Eshmuminov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Rordorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Veit-Haibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuno","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,9]]},"reference":[{"key":"4477_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"4477_CR2","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095\u2013128.","journal-title":"Lancet"},{"key":"4477_CR3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137\u201350.","journal-title":"J Clin Oncol"},{"key":"4477_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3322\/caac.21149","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220\u201341.","journal-title":"CA Cancer J Clin"},{"key":"4477_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"4477_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715\u201321.","journal-title":"J Clin Oncol"},{"key":"4477_CR7","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"4477_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","volume":"253","author":"K Becker","year":"2011","unstructured":"Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934\u20139.","journal-title":"Ann Surg"},{"key":"4477_CR9","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680\u20136.","journal-title":"Cancer"},{"key":"4477_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/01.sla.0000186170.38348.7b","volume":"242","author":"PM Schneider","year":"2005","unstructured":"Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP, Hoelscher AH. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684\u201392.","journal-title":"Ann Surg"},{"key":"4477_CR11","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1200\/JCO.2001.19.12.3058","volume":"19","author":"WA Weber","year":"2001","unstructured":"Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058\u201365.","journal-title":"J Clin Oncol"},{"key":"4477_CR12","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1200\/JCO.2006.06.7801","volume":"24","author":"K Ott","year":"2006","unstructured":"Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692\u20138.","journal-title":"J Clin Oncol"},{"key":"4477_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","volume":"8","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797\u2013805.","journal-title":"Lancet Oncol"},{"key":"4477_CR14","first-page":"25","volume":"58","author":"JR Siewert","year":"1987","unstructured":"Siewert JR, Holscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58:25\u201332.","journal-title":"Chirurg"},{"key":"4477_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejso.2016.08.020","volume":"43","author":"K Lehmann","year":"2017","unstructured":"Lehmann K, Eshmuminov D, Bauerfeind P, Gubler C, Veit-Haibach P, Weber A, Abdul-Rahman H, Fischer M, Reiner C, Schneider PM. 18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. Eur J Surg Oncol. 2017;43:196\u2013202.","journal-title":"Eur J Surg Oncol"},{"key":"4477_CR16","volume-title":"TNM classification of malignant Tumours","author":"L Sobin","year":"2009","unstructured":"Sobin L, Gospodarowicz MK, Wittekind C. TNM classification of malignant Tumours. 7th ed. New York, NY: Wiley-Liss; 2009.","edition":"7"},{"key":"4477_CR17","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17:1697\u2013708.","journal-title":"Lancet Oncol"},{"key":"4477_CR18","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ijc.26180","volume":"130","author":"N Homann","year":"2012","unstructured":"Homann N, Pauligk C, Luley K, Werner Kraus T, Bruch HP, Atmaca A, Noack F, Altmannsberger HM, Jager E, Al-Batran SE. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012;130:1706\u201313.","journal-title":"Int J Cancer"},{"key":"4477_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-540-70579-6_8","volume":"182","author":"M Schiesser","year":"2010","unstructured":"Schiesser M, Schneider PM. Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res. 2010;182:93\u2013106.","journal-title":"Recent Results Cancer Res"},{"key":"4477_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10120-011-0042-4","volume":"14","author":"Japanese Gastric Cancer A","year":"2011","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113\u201323.","journal-title":"Gastric Cancer"},{"key":"4477_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"4477_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jso.21592","volume":"102","author":"D Vallbohmer","year":"2010","unstructured":"Vallbohmer D, Holscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E, Baldus S, Alakus H, Brabender J, Metzger R. Monig SP: [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol. 2010;102:135\u201340.","journal-title":"J Surg Oncol"},{"key":"4477_CR23","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1078-0432.CCR-07-0934","volume":"14","author":"K Ott","year":"2008","unstructured":"Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res. 2008;14:2012\u20138.","journal-title":"Clin Cancer Res"},{"key":"4477_CR24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/sj.bjc.6603412","volume":"95","author":"CM Gillham","year":"2006","unstructured":"Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'Byrne K, Hollywood D, Muldoon C, Reynolds JV. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95:1174\u20139.","journal-title":"Br J Cancer"},{"key":"4477_CR25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/SLA.0b013e3181bc9c0d","volume":"250","author":"D Vallbohmer","year":"2009","unstructured":"Vallbohmer D, Holscher AH, Dietlein M, Bollschweiler E, Baldus SE, Monig SP, Metzger R, Schicha H, Schmidt M. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888\u201394.","journal-title":"Ann Surg"},{"key":"4477_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/SLA.0b013e3181f66596","volume":"253","author":"M van Heijl","year":"2011","unstructured":"van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011;253:56\u201363.","journal-title":"Ann Surg"},{"key":"4477_CR27","first-page":"690","volume":"44","author":"T Yoshioka","year":"2003","unstructured":"Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, Yamaura G, Takahashi H, Fukuda H, Kanamaru R. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44:690\u20139.","journal-title":"J Nucl Med"},{"key":"4477_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00259-001-0743-8","volume":"29","author":"T De Potter","year":"2002","unstructured":"De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, Maes A, Mortelmans L. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging. 2002;29:525\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4477_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00268-003-7191-5","volume":"28","author":"E Mochiki","year":"2004","unstructured":"Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28:247\u201353.","journal-title":"World J Surg"},{"key":"4477_CR30","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1245\/s10434-011-2147-8","volume":"19","author":"D Reim","year":"2012","unstructured":"Reim D, Gertler R, Novotny A, Becker K, zum Buschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H, Schumacher C. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108\u201318.","journal-title":"Ann Surg Oncol"},{"key":"4477_CR31","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1245\/s10434-012-2254-1","volume":"19","author":"S Lorenzen","year":"2012","unstructured":"Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119\u201327.","journal-title":"Ann Surg Oncol"},{"key":"4477_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-540-70579-6_5","volume":"182","author":"K Lehmann","year":"2010","unstructured":"Lehmann K, Schneider PM. Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res. 2010;182:65\u201372.","journal-title":"Recent Results Cancer Res"},{"key":"4477_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-3-540-70579-6_15","volume":"182","author":"G Lurje","year":"2010","unstructured":"Lurje G, Lenz HJ. Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2010;182:179\u201391.","journal-title":"Recent Results Cancer Res"},{"key":"4477_CR34","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/jnci\/djp341","volume":"101","author":"K Hede","year":"2009","unstructured":"Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009;101:1306\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"4477_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"4477_CR36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2967\/jnumed.110.085803","volume":"52","author":"CM zum Buschenfelde","year":"2011","unstructured":"zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52:1189\u201396.","journal-title":"J Nucl Med"},{"key":"4477_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-6649-8-3","volume":"8","author":"M van Heijl","year":"2008","unstructured":"van Heijl M, Omloo JM, van Berge Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM, Hoekstra OS, Stoker J, Hulshof MC, van der Gaast A, et al. NEOadjuvant therapy monitoring with PET and CT in esophageal Cancer (NEOPEC-trial). BMC Med Phys. 2008;8:3.","journal-title":"BMC Med Phys"},{"key":"4477_CR38","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.ejca.2008.06.005","volume":"44","author":"F Lordick","year":"2008","unstructured":"Lordick F, Ruers T, Aust DE, Collette L, Downey RJ, El Hajjam M, Flamen P, Haustermans K, Ilson D, Julie C, et al. European organisation of research and treatment of Cancer (EORTC) gastrointestinal group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer. 2008;44:1807\u201319.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4477-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T23:04:17Z","timestamp":1557356657000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4477-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4477"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4477-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,9]]},"assertion":[{"value":"12 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee, Kantonale Ethikkommission Z\u00fcrich, Stampfenbachstrasse 121, 8090 Z\u00fcrich, Tel +\u200941 (0)43259 79 70 and registered under registration number PB 2016\u201300769. The need for written informed consent form from each patient has been waived by ethics committee due to retrospective manner of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"548"}}